Neoadjuvant chemoradiotherapy plus sintilimab in pMMR/MSS rectal cancer patients with PD-L1 TPS ≥ 1% or CPS ≥ 1: an open-label, prospective, phase II study
新辅助放化疗联合信迪利单抗治疗PD-L1 TPS≥1%或CPS≥1的pMMR/MSS直肠癌患者:一项开放标签、前瞻性II期研究
期刊:npj Precision Oncology
影响因子:8
doi:10.1038/s41698-025-01018-0
Hou, Zhenlin; Liao, Leen; Xiao, Weiwei; Sui, Qiaoqi; Han, Kai; Xiao, Binyi; Li, Yuan; Mei, Weijian; Yu, Jiehai; Hong, Zhigang; Chen, Qichen; Song, Ruyue; Li, Dandan; Zhang, Xiaoshi; Wang, Qiaoxuan; Pan, Zhizhong; Jiang, Wu; Ding, Peirong
多发性骨髓瘤
PD-L1
肿瘤
多发性硬化症
肠癌
肿瘤免疫